Adverse events following human papillomavirus vaccine in adolescents in the state of Minas Gerais

Authors

DOI:

https://doi.org/10.35699/2316-9389.2022.40892

Keywords:

Vaccination, Adolescent, Epidemiology, Drug-Related Side Effects and Adverse Reactions, Information Systems

Abstract

Objective: to investigate reports of adverse events following human papillomavirus vaccination in the state of Minas Gerais, according to the location of notification, causality, severity, and evolution of cases. Methods: epidemiological study carried out with data from 2015-2019, reported in the Adverse Event Surveillance Information System. Data were analyzed and presented in proportions, according to health macro-regions and years of study. Results: in 2015, 26.41% of adverse events were reported, being the year with the highest number of notifications. In the analysis of health macro-regions, Vale do Jequitinhonha had the lowest prevalence of registration (0.43%), and the Center had the highest prevalence of notification (30.95%). The most prevalent local adverse events were pain (56.48%) and edema (38.89%). As for systemic events, headache (29.69%) and gastroenteritis (29.69%) had the highest number of cases. Events classified as non-serious adverse events (59.82%) were the most prevalent, and regarding the cause, 35.94% of them were attributed to immunization errors. Conclusion: this study reinforces that adverse events following HPV vaccination were, for the most part, non-serious events, thus demonstrating the safety of the HPV vaccine for the adolescent public, contributing to the increase in vaccine coverage rates.

Downloads

Download data is not yet available.

References

Domingues CMAS, Teixeira AM da S, Carvalho SMD. National immunization program: vaccination, compliance and pharmacovigilance. Rev Inst Med Trop Sao Paulo. 2012[citado em 2022 jan. 18];54(suppl.18):22–7. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46652012000700009&lng=en&nrm=iso&tlng=en

Lima AA, Pinto ES. O contexto histórico da implantação do Programa Nacional de Imunização (PNI) e sua importância para o Sistema Único de Saúde (SUS). Scire Salutis. 2017[citado em 2022 jan. 18];17(1):53-62. Disponível em: http://doi.org/10.6008/SPC2236-9600.2017.001.0005

Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Departamento de Imunizações e Doenças Transmissíveis. Manual de vigilância epidemiológica de eventos adversos pós-vacinação. Brasília (DF): MS; 2020. 340 p. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_epidemiologica_eventos_vacinacao_4ed.pdf

World Health Organization. Definition and Application of Terms for Vaccine Pharmacovigilance This report from the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO covers the activities and outputs of the CIOMS/WHO Working Group on. Genova (CH): WHO; 2012. Disponível em: https://vaccine-safety-training.org/tl_files/vs/pdf/report-of-cioms-who-working-group.pdf

Principi N, Esposito S. Adverse events following immunization: real causality and myths. Expert Opin Drug Saf. 2016[citado em 2022 fev. 22];15(6):825-35. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26986067/

Mc Cracken H. Why so many kids are not immunized against HPV |Pittsburgh Post-Gazette. J Pittsburgh Post-Gazzete. 2015[citado em 2022 fev. 22]. Disponível em: http://www.postgazette.com/news/health/2015/09/13/The-cancer-vaccine-Why-so-many-kidsare-not-immunized-against-HPV/stories/201509130121

Linder-Ganz R, Efrati I. Cervical câncer vaccine for Israeli schoolgirls meets religion opposition. J Haaretz. 2013[citado em 2022 fev. 22]. Disponível em: https://www.haaretz.com/.premium-haredim-oppose-st

Borsatto AZ, Vidal MLB, Rocha RCNP. Vacina contra o HPV e a Prevenção do Câncer do Colo do Útero: Subsídios para a Prática. Rev Bras Cancerol. 2011[citado em 2022 ago 21];57(1):67-74. Disponível em: https://rbc.inca.gov.br/index.php/revista/article/view/690

Duarte Osis MJ. Conhecimento e atitude de usuários do SUS sobre o HPV e as vacinas disponíveis no Brasil SUS users’ knowledge of and attitude to HPV virus and vaccines available in Brazil. Rev Saúde Pública. 2014[citado em 2022 ago 21];48(1):123-33. Disponível em: http://www.brasil.gov.br/saude/2013/09/cobertura-da-vacina-hpv-sera-ampliada-a-partir-de-2014

Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: a systematic review & meta-analysis. BMC Infect Dis. 2011[citado em 2022 ago 21]; 11:13. Disponível em: https://pubmed.ncbi.nlm.nih.gov/21226933/

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020[citado em 2022 ago 21];395(10224):575-90. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32007141/

Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020[citado em 2022 ago 21];395(10224):591-603. Disponível em: https://sustainabledevelopment

Moura LL, Codeço CT, Luz PM. Human papillomavirus (HPV) vaccination coverage in Brazil: Spatial and age cohort heterogeneity. Rev Bras Epidemiol. 2021[citado em 2022 ago 21];24:1-12. Disponível em: https://doi.org/10.1590/1980-549720210001

Ministério da Saúde (BR). Informe Técnico Sobre a Vacina Papilomavírus Humano (Hpv) Na Atenção Básica. Brasília (DF): Ministério da Saúde; 2014. 36

Instituto Nacional de Geografia e Estatística. Estimativas da população residente no brasil e unidades da federação com data de referência em 1o de julho de 2019. Rio de Janeiro: IBGE; 2019.

Conselho Nacional de Saúde (BR). Resolução nº466/2012 do Conselho Nacional de Saúde. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos e revoga as Resoluções CNS nos. 196/96, 303/2000 e 404/2008. Brasília (DF): CNS; 2012. Disponível em: https://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf

Waldman EA, Luhm KR, Monteiro SAMG, Freitas FRM de. Vigilância de eventos adversos pós-vacinação e segurança de programas de imunização. Rev Saúde Pública. 2011[citado em 2021 maio 17];45(1):173-84. Disponível em: https://pubmed.ncbi.nlm.nih.gov/21181055/

Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine. 2018 [citado em 2021 maio 17];36(13):1781-8. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29477308/

Pacheco FC, Domingues CMAS, Maranhão AGK, Carvalho SMD, Silva TAM, Braz RM, et al. Analysis of the Vaccine Adverse Event Reporting System in Brazil, 2014 to 2016. Rev Panam Salud Publica. 2018[citado em 2022 maio 12];7;42:e12. Disponível em: https://www.scielosp.org/pdf/rpsp/2018.v42/e12/pt

Viacava F, Oliveira RAD, Carvalho CC, Laguardia J, Bellido JG. SUS: Supply, access to and use of health services over the last 30 years. Ciênc Saúde Colet. 2018[citado em 2022 maio 12];23(6):1751–62. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232018000601751&lng=en&nrm=iso&tlng=pt

Paula FA, Silva CCR, Santos DF, Martins-Filho OA, Andrade RA. Avaliação da atenção à saúde do adulto em um município-polo do Vale do Jequitinhonha (MG). Saúde Debate. 2015;[citado em 2022 maio 12];39(106):802-14. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042015000300802&lng=en&nrm=iso&tlng=pt

Soares JJN, Machado MH, Alves CB. O programa Mais Médicos, a infraestrutura das unidades básicas de saúde e o Índice de desenvolvimento humano municipal. Ciênc Saúde Colet. 2016[citado em 2022 maio 12];21(9):2709-18. Disponível em: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-81232016000902709&lng=en&nrm=iso&tlng=pt

Liu XC, Bell CA, Simmonds KA, Svenson LW, Russell ML. Adverse events following HPV vaccination, Alberta 2006-2014. Vaccine. 2016[citado em 2022 maio 12];34(15):1800-5. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26921782/

Harris T, Williams DM, Fediurek J, Scott T, Deeks SL. Adverse events following immunization in Ontario’s female school-based HPV program. Vaccine. 2014[citado em 2022 maio 12];32(9):1061-6. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24440208/

NCIRS National Centre for Immunisation Research and Surveillance. Evaluation of the National Human Papillomavirus Vaccination Program Final Report. Westmead (AU): Department of Health; 2014[citado em 2022 maio 12]. Disponível em: https://www.health.gov.au/sites/default/files/evaluation-national-hpv-program.pdf

World Health Organization. Module 4: Surveillance. 2012. Disponível em: https://apps.who.int/iris/handle/10665/66968?show=full

Šubelj M, Učakar V, Kraigher A, Klavs I. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013. Euro Surveill. 2016[citado em 2022 mar. 13];21(14). Disponível em: 10.2807/1560-7917.ES.2016.21.14.30187

Santana CF Pereira LS, Costa N. Eventos adversos pós-vacinais da vacina contra o HPV no município de Anápolis, Goiás. Rev Educ Saúde. 2016[citado em 2021 dez. 10];4(2):72–9. Disponível em: http://periodicos.unievangelica.edu.br/index.php/educacaoemsaude/article/view/2019

Published

2022-12-21

How to Cite

1.
Luvisaro BMO, Silva TPR, Felisbino-Mendes MS, Silva TMR da, Silva RB da, Lachtim SAF, Freitas GL de, Matozinhos FP. Adverse events following human papillomavirus vaccine in adolescents in the state of Minas Gerais. REME Rev Min Enferm. [Internet]. 2022 Dec. 21 [cited 2024 May 12];26. Available from: https://periodicos.ufmg.br/index.php/reme/article/view/40892

Issue

Section

Research

Most read articles by the same author(s)

<< < 1 2